Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development)

✍ Scribed by Lloyd R. Kelland (Editor), Nicholas Farrell (Editor)

Year: 2000
Tongue: English
Leaves: 354
Edition: 1
Category: Library

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiangiogenic Agents in Cancer Therapy

📁 Antiangiogenic Agents in Cancer Therapy (Cancer Drug Discovery and Development) (Cancer Drug Discovery and Development)

✍ Beverly A. Teicher, Lee M. Ellis 📂 Library 📅 2007 🏛 Humana Press 🌐 English

Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials. Optimizing the therapeutic potential of antiangiogenic agents in combination with the other

Platinum-Based Drugs in Cancer Therapy

📁 Platinum-Based Drugs in Cancer Therapy

✍ Susan J. Berners-Price, Trevor G. Appleton (auth.), Lloyd R. Kelland, Nicholas P 📂 Library 📅 2000 🏛 Humana Press 🌐 English

<p>In Platinum-Based Drugs in Cancer Therapy, leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss th

Drug Delivery Systems in Cancer Therapy

📁 Drug Delivery Systems in Cancer Therapy (Cancer Drug Discovery and Development)

✍ Dennis M. Brown 📂 Library 📅 2003 🌐 English

Leading experts survey the currently available technologies designed to improve the delivery of today's cancer chemotherapeutic agents. The authors review both the theoretical and practical considerations governing conventional and nonconventional methods of drug administration, and identify promisi

Fluoropyrimidines in Cancer Therapy (Can

📁 Fluoropyrimidines in Cancer Therapy (Cancer Drug Discovery and Development)

✍ Youcef M. Rustum 📂 Library 📅 2002 🌐 English

Leading cancer researchers update and review the mechanisms of action and the therapeutic selectivity and efficacy of 5-FU with and without leucovorin and its prodrugs in the treatment of colorectal cancer. Among the combination agents considered are UFT/LV, 5-FU/EU, capecitabine (Xeloda), S-1, and

Chemoradiation in Cancer Therapy (Cancer

📁 Chemoradiation in Cancer Therapy (Cancer Drug Discovery and Development)

✍ Hak Choy 📂 Library 📅 2002 🌐 English

Internationally recognized experts in cancer biology and clinical research review the present status of the multimodality approach to the management of solid tumors and speculate on possible future strategies for chemoradiation therapy. The authors detail applications of combined modality therapy in

Camptothecins in Cancer Therapy (Cancer

📁 Camptothecins in Cancer Therapy (Cancer Drug Discovery and Development)

✍ Val R. Adams 📂 Library 📅 2005 🏛 Humana Press 🌐 English

A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a va